1-2 of 2
Christine Pivot, Pharm.
Close
Sort by
Journal Articles

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Franck E. Nicolini, MD, PhD, Gabriel Etienne, MD, PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, Laurence Legros, MD, PhD, Stephane Giraudier, MD, PhD, Valérie Coiteux, MD, Agnès Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, MD, PhD, Shanti Ame, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Stephane Morisset, Stat., Christine Pivot, Pharm., Madeleine Etienne, CRA, François Guilhot, MD, Stephanie Dulucq, MD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 166.
https://doi.org/10.1182/blood.V120.21.166.166
Published: 2012
Journal Articles

Erythropoietin Use In Patients with AML or Undergoing Allogeneic HSCT Significantly Improves Quality of Life and Reduces Red Blood Cells and Platelets Transfusions without Any Survival Effect.

Mauricette Michallet, Karine Goldet, CRA, Stephane Morisset, Stat., Mohamad Sobh, Pharm., M., Youcef Chelghoum, MD, Xavier Thomas, MD, PhD, Helene Labussiere, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Jean Vial, Catherine Renzullo, Pharm., Carole Paillet, Pharm., Christine Pivot, Pharm., Perrine Badol-Van Straaten, Angelique Denis, Anne Termoz, Franck E Nicolini, MD, PhD, Isabelle Jaisson-Hot
Journal: Blood
Blood (2010) 116 (21): 3810.
https://doi.org/10.1182/blood.V116.21.3810.3810
Published: 2010